New combo therapy shows promise for tough prostate cancer

NCT ID NCT02225704

Completed Disease control Sponsor: Cancer Trials Ireland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving two drugs together—Radium-223 and enzalutamide—is safe for men with advanced prostate cancer that has spread to other parts of the body and is no longer controlled by standard hormone therapy. 45 men took part. The main goal was to track serious side effects, and researchers also looked at how long it took for the cancer to worsen. The approach aims to better control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Cork University Hospital

Cork, Ireland
Galway University Hospital

Galway, Ireland
Mater Misericordiae University Hospital

Dublin, Ireland
Mater Private Hospital

Dublin, Ireland
SLRON, St James's Hospital

Dublin, Ireland
St Vincents University Hospital / AMNCH

Dublin, Ireland
Tallaght Hospital

Dublin, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.